AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Dyadic International, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Dyadic International, Inc. (Nasdaq: DYAI) filed a Form 8-K on 2 July 2025 to disclose a branding update. In 30 days the company will begin operating under the business name “Dyadic Applied BioSolutions.â€� The filing clarifies that the legal corporate name remains “Dyadic International, Inc.,â€� the DYAI ticker is unchanged, and the company will continue to trade on the Nasdaq Stock Market. The disclosure is provided under Item 7.01 (Regulation FD) and is furnished—not filed—thereby carrying no Section 18 liability and no direct impact on financial statements. No financial data, operational revisions, or strategic transactions are included; the report solely communicates the forthcoming DBA designation and furnishes the related press release as Exhibit 99.1.

Dyadic International, Inc. (Nasdaq: DYAI) ha presentato un modulo 8-K il 2 luglio 2025 per comunicare un aggiornamento del marchio. Tra 30 giorni, la società inizierà a operare con il nome commerciale “Dyadic Applied BioSolutions.� Nel documento si specifica che il nome legale rimane “Dyadic International, Inc.,� il ticker DYAI non cambia e la società continuerà a essere quotata sul Nasdaq Stock Market. La comunicazione è fornita ai sensi della voce 7.01 (Regulation FD) ed è messa a disposizione, non depositata, quindi non comporta responsabilità ai sensi della Sezione 18 né impatti diretti sui bilanci. Non sono inclusi dati finanziari, modifiche operative o transazioni strategiche; il rapporto si limita a comunicare la futura denominazione DBA e allega il comunicato stampa correlato come Exhibit 99.1.

Dyadic International, Inc. (Nasdaq: DYAI) presentó un Formulario 8-K el 2 de julio de 2025 para anunciar una actualización de marca. En 30 días, la empresa comenzará a operar bajo el nombre comercial “Dyadic Applied BioSolutions.â€� El documento aclara que el nombre legal corporativo sigue siendo “Dyadic International, Inc.,â€� el símbolo DYAI no cambia y la compañía continuará cotizando en el Nasdaq Stock Market. La divulgación se realiza bajo el Ãtem 7.01 (Regulación FD) y se proporciona, no se presenta formalmente, por lo que no implica responsabilidad bajo la Sección 18 ni afecta directamente los estados financieros. No se incluyen datos financieros, cambios operativos ni transacciones estratégicas; el informe solo comunica la próxima designación DBA y adjunta el comunicado de prensa relacionado como Exhibit 99.1.

Dyadic International, Inc. (나스ë‹�: DYAI)ëŠ� 2025ë…� 7ì›� 2ì� 브랜ë“� ì—…ë°ì´íЏë¥� 공개하기 위해 Form 8-Kë¥� 제출했습니다. 30ì� í›� 회사ëŠ� “Dyadic Applied BioSolutions.â€�ë¼ëŠ” ìƒí˜¸ë¡� ìš´ì˜ì� 시작í•� 예정입니ë‹�. 제출 서류ëŠ� ë²•ì  ë²•ì¸ëª…ì€ ì—¬ì „íž� “Dyadic International, Inc.â€ì´ë©�, DYAI 티커ëŠ� 변경ë˜ì§€ 않고 회사ëŠ� 계ì†í•´ì„œ 나스ë‹� ì¦ê¶Œê±°ëž˜ì†Œì—ì„� 거래ëœë‹¤ê³� 명확íž� ë°í˜”습니ë‹�. ì� 공시ëŠ� 항목 7.01(Regulation FD)ì—� ë”°ë¼ ì œê³µë˜ì—ˆìœ¼ë©° 제출ë� ê²ƒì´ ì•„ë‹ˆë� 제공ë� 것으ë¡�, 섹션 18 ì±…ìž„ì� 없고 재무제표ì—� ì§ì ‘ì ì¸ ì˜í–¥ì� 없습니다. 재무 ë°ì´í„�, ìš´ì˜ ë³€ê²� ë˜ëŠ” ì „ëžµì � 거래ëŠ� í¬í•¨ë˜ì–´ 있지 않으ë©�, 보고서는 다가오는 DBA 명칭 ë³€ê²½ì„ ì•Œë¦¬ê³� ê´€ë � ë³´ë„ìžë£Œë¥� Exhibit 99.1ë¡� 첨부하는 ë°ì—ë§� 목ì ì� 있습니다.

Dyadic International, Inc. (Nasdaq : DYAI) a déposé un formulaire 8-K le 2 juillet 2025 pour annoncer une mise à jour de sa marque. Dans 30 jours, la société commencera à opérer sous le nom commercial « Dyadic Applied BioSolutions. » Le dépôt précise que le nom légal reste « Dyadic International, Inc. », que le symbole DYAI ne change pas et que la société continuera à être cotée au Nasdaq Stock Market. Cette divulgation est fournie en vertu de l’article 7.01 (Regulation FD) et est fournie � non déposée � ce qui exclut toute responsabilité au titre de la Section 18 et n’a aucun impact direct sur les états financiers. Aucune donnée financière, modification opérationnelle ou transaction stratégique n’est incluse ; le rapport communique uniquement la future désignation DBA et fournit le communiqué de presse associé en tant qu’Exhibit 99.1.

Dyadic International, Inc. (Nasdaq: DYAI) reichte am 2. Juli 2025 ein Formular 8-K ein, um ein Branding-Update bekannt zu geben. In 30 Tagen wird das Unternehmen unter dem Geschäftsnamen „Dyadic Applied BioSolutions.� auftreten. In der Einreichung wird klargestellt, dass der rechtliche Firmenname weiterhin „Dyadic International, Inc.� lautet, das DYAI-Tickersymbol unverändert bleibt und das Unternehmen weiterhin an der Nasdaq Stock Market gehandelt wird. Die Offenlegung erfolgt gemäß Punkt 7.01 (Regulation FD) und wird bereitgestellt � nicht eingereicht � wodurch keine Haftung nach Abschnitt 18 entsteht und keine direkten Auswirkungen auf die Finanzberichte vorliegen. Es sind keine Finanzdaten, operativen Änderungen oder strategischen Transaktionen enthalten; der Bericht informiert ausschließlich über die bevorstehende DBA-Bezeichnung und enthält die zugehörige Pressemitteilung als Exhibit 99.1.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Name-only rebranding; no change to DYAI’s financial outlook or Nasdaq listing—overall neutral.

Investors face no immediate economic consequences from the new DBA. The filing contains no revenue, cost, or guidance updates, and the legal entity, reporting obligations, and ticker symbol remain intact. As such, valuation models and risk profiles should remain unchanged. Branding exercises can signal strategic repositioning, but without supporting detail this event is non-material for near-term cash flows or capital structure.

TL;DR: Administrative disclosure compliant with Reg FD; governance impact minimal.

The company properly used Item 7.01 to furnish market-wide notice, limiting liability exposure. Because the legal name is preserved, charter documents and existing contracts require no amendments. The 30-day lead time affords counterparties notice, while retaining the DYAI symbol avoids market-confusion. Overall governance risk remains unchanged.

Dyadic International, Inc. (Nasdaq: DYAI) ha presentato un modulo 8-K il 2 luglio 2025 per comunicare un aggiornamento del marchio. Tra 30 giorni, la società inizierà a operare con il nome commerciale “Dyadic Applied BioSolutions.� Nel documento si specifica che il nome legale rimane “Dyadic International, Inc.,� il ticker DYAI non cambia e la società continuerà a essere quotata sul Nasdaq Stock Market. La comunicazione è fornita ai sensi della voce 7.01 (Regulation FD) ed è messa a disposizione, non depositata, quindi non comporta responsabilità ai sensi della Sezione 18 né impatti diretti sui bilanci. Non sono inclusi dati finanziari, modifiche operative o transazioni strategiche; il rapporto si limita a comunicare la futura denominazione DBA e allega il comunicato stampa correlato come Exhibit 99.1.

Dyadic International, Inc. (Nasdaq: DYAI) presentó un Formulario 8-K el 2 de julio de 2025 para anunciar una actualización de marca. En 30 días, la empresa comenzará a operar bajo el nombre comercial “Dyadic Applied BioSolutions.â€� El documento aclara que el nombre legal corporativo sigue siendo “Dyadic International, Inc.,â€� el símbolo DYAI no cambia y la compañía continuará cotizando en el Nasdaq Stock Market. La divulgación se realiza bajo el Ãtem 7.01 (Regulación FD) y se proporciona, no se presenta formalmente, por lo que no implica responsabilidad bajo la Sección 18 ni afecta directamente los estados financieros. No se incluyen datos financieros, cambios operativos ni transacciones estratégicas; el informe solo comunica la próxima designación DBA y adjunta el comunicado de prensa relacionado como Exhibit 99.1.

Dyadic International, Inc. (나스ë‹�: DYAI)ëŠ� 2025ë…� 7ì›� 2ì� 브랜ë“� ì—…ë°ì´íЏë¥� 공개하기 위해 Form 8-Kë¥� 제출했습니다. 30ì� í›� 회사ëŠ� “Dyadic Applied BioSolutions.â€�ë¼ëŠ” ìƒí˜¸ë¡� ìš´ì˜ì� 시작í•� 예정입니ë‹�. 제출 서류ëŠ� ë²•ì  ë²•ì¸ëª…ì€ ì—¬ì „íž� “Dyadic International, Inc.â€ì´ë©�, DYAI 티커ëŠ� 변경ë˜ì§€ 않고 회사ëŠ� 계ì†í•´ì„œ 나스ë‹� ì¦ê¶Œê±°ëž˜ì†Œì—ì„� 거래ëœë‹¤ê³� 명확íž� ë°í˜”습니ë‹�. ì� 공시ëŠ� 항목 7.01(Regulation FD)ì—� ë”°ë¼ ì œê³µë˜ì—ˆìœ¼ë©° 제출ë� ê²ƒì´ ì•„ë‹ˆë� 제공ë� 것으ë¡�, 섹션 18 ì±…ìž„ì� 없고 재무제표ì—� ì§ì ‘ì ì¸ ì˜í–¥ì� 없습니다. 재무 ë°ì´í„�, ìš´ì˜ ë³€ê²� ë˜ëŠ” ì „ëžµì � 거래ëŠ� í¬í•¨ë˜ì–´ 있지 않으ë©�, 보고서는 다가오는 DBA 명칭 ë³€ê²½ì„ ì•Œë¦¬ê³� ê´€ë � ë³´ë„ìžë£Œë¥� Exhibit 99.1ë¡� 첨부하는 ë°ì—ë§� 목ì ì� 있습니다.

Dyadic International, Inc. (Nasdaq : DYAI) a déposé un formulaire 8-K le 2 juillet 2025 pour annoncer une mise à jour de sa marque. Dans 30 jours, la société commencera à opérer sous le nom commercial « Dyadic Applied BioSolutions. » Le dépôt précise que le nom légal reste « Dyadic International, Inc. », que le symbole DYAI ne change pas et que la société continuera à être cotée au Nasdaq Stock Market. Cette divulgation est fournie en vertu de l’article 7.01 (Regulation FD) et est fournie � non déposée � ce qui exclut toute responsabilité au titre de la Section 18 et n’a aucun impact direct sur les états financiers. Aucune donnée financière, modification opérationnelle ou transaction stratégique n’est incluse ; le rapport communique uniquement la future désignation DBA et fournit le communiqué de presse associé en tant qu’Exhibit 99.1.

Dyadic International, Inc. (Nasdaq: DYAI) reichte am 2. Juli 2025 ein Formular 8-K ein, um ein Branding-Update bekannt zu geben. In 30 Tagen wird das Unternehmen unter dem Geschäftsnamen „Dyadic Applied BioSolutions.� auftreten. In der Einreichung wird klargestellt, dass der rechtliche Firmenname weiterhin „Dyadic International, Inc.� lautet, das DYAI-Tickersymbol unverändert bleibt und das Unternehmen weiterhin an der Nasdaq Stock Market gehandelt wird. Die Offenlegung erfolgt gemäß Punkt 7.01 (Regulation FD) und wird bereitgestellt � nicht eingereicht � wodurch keine Haftung nach Abschnitt 18 entsteht und keine direkten Auswirkungen auf die Finanzberichte vorliegen. Es sind keine Finanzdaten, operativen Änderungen oder strategischen Transaktionen enthalten; der Bericht informiert ausschließlich über die bevorstehende DBA-Bezeichnung und enthält die zugehörige Pressemitteilung als Exhibit 99.1.

false 0001213809 0001213809 2025-07-02 2025-07-02
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 8-K
 

 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (date of earliest event reported): July 2, 2025
 

 
Dyadic International, Inc.
(Exact name of registrant as specified in its charter)
 

 
Delaware 000-55264 45-0486747
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification Number)
 
1044 North U.S. Highway One, Suite 201
Jupiter, FL 33477
(Address of principal executive offices and zip code)
 
(561) 743-8333
(Registrant’s telephone number, including area code)
 
N/A
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
   
Securities registered pursuant to Section 12(b) of the Act
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
DYAI
The Nasdaq Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
Item 7.01 Regulation FD Disclosure.
 
On July 2, 2025, Dyadic International, Inc. (the “Company”) issued a press release announcing that, effective in 30 days, it will be doing business under the name “Dyadic Applied BioSolutions.” The Company’s legal name will remain “Dyadic International, Inc.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
 
The information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. Such information shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
 
Item 9.01 Financial Statements and Exhibits.
 
 
(d) Exhibits
   
Exhibit Number
Description
 
99.1
Dyadic International, Inc. Press Release dated July 2, 2025.
 
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: July 2, 2025
Dyadic International, Inc.
By:
/s/ Ping Rawson
Name:
Ping Rawson
Title:
Chief Financial Officer
   
 

FAQ

Why is Dyadic International (DYAI) issuing an 8-K on July 2, 2025?

To announce that it will begin doing business as Dyadic Applied BioSolutions effective in 30 days.

When does the new DBA "Dyadic Applied BioSolutions" become effective?

The change takes effect 30 days after the July 2, 2025 press release.

Will Dyadic’s legal corporate name or Nasdaq ticker change?

No. The legal name remains Dyadic International, Inc. and the ticker stays DYAI.

Does the rebranding affect Dyadic’s financial statements or guidance?

The 8-K includes no financial data and states the information is furnished, not filed; financials are unaffected.

Where can investors read the full press release about the name change?

It is filed as Exhibit 99.1 to the Form 8-K dated July 2, 2025.

Which SEC item does Dyadic use to disclose the DBA change?

Item 7.01 (Regulation FD Disclosure).
Dyadic Intl Inc Del

NASDAQ:DYAI

DYAI Rankings

DYAI Latest News

DYAI Latest SEC Filings

DYAI Stock Data

29.58M
20.97M
30.15%
17.3%
0.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
JUPITER